Clinical Trial Update: Acthar for Treatment of Post-transplant FSGS [Phase 4]

View source ↗

Summary

Phase 4 trial of Acthar for post-transplant focal segmental glomerulosclerosis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis
• Kidney Transplant Failure

Drugs mentioned

• Acthar (repository corticotropin injection)

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: FSGS, Renal Transplantation | Phase 4 | Status: WITHDRAWN